期刊
ACTA NEUROPATHOLOGICA COMMUNICATIONS
卷 5, 期 -, 页码 -出版社
BMC
DOI: 10.1186/s40478-017-0475-z
关键词
Alzheimer's disease; iPSC; BFCN; CRISPR/Cas9; Electrophysiology; Basal forebrain; Cholinergic; Presenilin; PSEN2
资金
- Charles Evans Foundation
- Alzheimer's Drug Discovery Foundation
- The NY Community Trust
- Cure Alzheimer's Fund [R21AG042965, U01AG046170]
- National Institutes of Health (NIH) [R21AG042965, U01AG046170]
- Werber Family Foundation
- Scott and Jennifer Moskowitz Foundation
- Stuart Katz and Dr Jane Martin Foundation
- Louis B. Mayer Foundation
- Georgianne and Dr. Reza Khatib Foundation
- Sarah and Gideon Gartner Foundation
- NIH [NS049442]
- Mount Sinai Alzheimer's Disease Research Center [P50 AG05138]
Basal forebrain cholinergic neurons (BFCNs) are believed to be one of the first cell types to be affected in all forms of AD, and their dysfunction is clinically correlated with impaired short- term memory formation and retrieval. We present an optimized in vitro protocol to generate human BFCNs from iPSCs, using cell lines from presenilin 2 (PSEN2) mutation carriers and controls. As expected, cell lines harboring the PSEN2(N141I) mutation displayed an increase in the A beta 42/40 in iPSC-derived BFCNs. Neurons derived from PSEN2(N141I) lines generated fewer maximum number of spikes in response to a square depolarizing current injection. The height of the first action potential at rheobase current injection was also significantly decreased in PSEN2(N141I) BFCNs. CRISPR/Cas9 correction of the PSEN2 point mutation abolished the electrophysiological deficit, restoring both the maximal number of spikes and spike height to the levels recorded in controls. Increased A beta 42/40 was also normalized following CRISPR/Casmediated correction of the PSEN2(N141I) mutation. The genome editing data confirms the robust consistency of mutation-related changes in A beta 42/40 ratio while also showing a PSEN2-mutation-related alteration in electrophysiology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据